With this in mind, the use of nonselective PPAR pan-agonists that interact with PPARα, PPARβ, and PPARγ with a balanced activation profile is a promising new strategy for the treatment of T2DM. The gene discussed is PPARA; the disease is type 2 diabetes mellitus.